Carlo M. Croce, MD, Recipient of the 2011 AMP Award for Excellence in Molecular Diagnostics
Carlo M. Croce, MD is being honored for his contributions involving the genes and genetic mechanisms implicated in the pathogenesis of human cancer. During the course of his career, he discovered the juxtaposition of the human immunoglobulin genes to the MYC oncogene and the deregulation of MYC in Burkitt lymphoma, the ALL1/MLL gene involved in acute leukemias, the TCL1 gene associated with T-cell leukemias, and cloned, named and characterized many oncogenes including the BCL2 gene involved in follicular lymphoma as well as several tumor suppressor genes. He uncovered the early events involved in the pathogenesis of lung, nasopharyngeal, head and neck, esophageal, gastrointestinal and breast cancers. His discoveries have led to revolutionary innovations in the development of approaches to cancer prevention, diagnosis, monitoring and treatment, based on gene-target discovery, verification and rational drug development. Recently he discovered the role of a new class of cancer genes encoding microRNAs. >>Read the Article
Dr. Croce earned his medical degree in 1969 from the School of Medicine, University of Rome and began his career at the Wistar Institute in Philadelphia. In 1991, he was named Director of the Kimmel Cancer Center at Thomas Jefferson University in Philadelphia during which time he discovered the role of microRNAs in cancer pathogenesis and progression, implicating a new class of genes in cancer causation. In 2004 he moved to The Ohio State University.
He has received almost every significant award for cancer research that one can earn, is a member of the National Academy of Sciences USA and most recently, an Elected Membership to The American Academy of Arts and Sciences. He is principal investigator on eleven federal research grants and has more than 900 peer-reviewed, published research papers.